SUNRISE, Fla., July 30 /PRNewswire-FirstCall/ -- Bioheart, Inc., (Nasdaq: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced financial results for the second quarter ended June 30, 2008.
Recent Clinical Highlights:
-- On July 24, 2008, we announced that the results of a preclinical study involving the injection of myoblasts modified to express stromal derived factor-1(alpha) protein (SDF-1) into the scar tissue of the myocardium of rats, which suggest improved heart function, were recently presented at two scientific meetings -- the International Society for Magnetic Resonance in Medicine (ISMRM) in Toronto, and the American Society of Gene Therapy Meeting (ASGT) in Boston.
-- The May 2008 issue of Cath Lab Digest featured an article on MyoCell(R) Clinical Cell Therapy, the SEISMIC Trial and an interview with Warren Sherman, MD, Director, Cardiac Cell-based Endovascular Therapies, Columbia University Medical Center, New York, New York and Principal Investigator of the MYOHEART Trial and the Phase II/III MARVEL Trial.
Recent Corporate Highlights:
-- On July 11, 2008 the Company announced that it secured worldwide
non-exclusive distribution rights to the Bioheart 3370 Heart Failure
Monitor, an interactive and simple-to-use at-home intelligent device
designed specifically to improve available healthcare to patients outside
hospitals who are suffering from heart failure. The device, manufactured by
RTX Healthcare A/S (Denmark), has 510k market clearance from the U.S. Food
and Drug Administration for marketing in the U.S. and CE mark approval for
marketing in Europe and other countries that
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved